# Dare Bioscience, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Dare Bioscience, Inc.). ## Overview Dare Bioscience, Inc. is a women’s health biopharmaceutical company developing and commercializing proprietary products across contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause. The company is shifting from a pure development model toward a capital-efficient commercialization model that combines late-stage R&D with near-term revenue opportunities through Section 503B compounded products and consumer health offerings. ## Products & services • Ovaprene® non-hormonal contraceptive candidate • XACIATO™ vaginal gel for bacterial vaginosis • DARE to PLAY™ Sildenafil Cream • DARE-HRT1 monthly estradiol/progesterone product • DARE-VVA1 and DARE-HPV development programs • DARE to RESTORE™ vaginal probiotic consumer products - **Commercialized and near-term commercial products** (20%) — Includes XACIATO and planned Section 503B/consumer health offerings such as DARE to PLAY Sildenafil Cream and DARE to RESTORE. - **Late-stage women’s health product candidates** (35%) — Includes Ovaprene and DARE-HRT1, which are being advanced toward clinical and commercial milestones. - **Early-stage clinical and preclinical programs** (25%) — Includes DARE-VVA1, DARE-HPV and other pipeline assets still in development. - **Grant-funded development programs** (20%) — Programs supported by non-dilutive grants, including work tied to DARE-LARC1, Ovaprene and DARE-HPV. - Ovaprene® contraceptive product candidate - XACIATO™ vaginal gel for bacterial vaginosis - DARE to PLAY™ Sildenafil Cream under Section 503B - DARE-HRT1 monthly estradiol/progesterone program - DARE-VVA1 and DARE-HPV clinical development programs - DARE to RESTORE™ vaginal probiotic consumer health line ## Customers Dare’s direct customers are healthcare providers, outsourcing facilities, telehealth partners, and third-party commercial partners that help bring its products to market. End users are women seeking solutions in contraception, sexual health, vaginal health, menopause, and related conditions, with some products intended for prescription use and others for consumer health channels. - **Women’s health providers** (primary) — Prescribe or recommend products such as Sildenafil Cream, XACIATO and future pipeline therapies because they address unmet women’s health needs. - **Telehealth and consumer health partners** (primary) — Help market and distribute non-prescription products like DARE to RESTORE and support direct-to-consumer awareness. - **503B outsourcing facilities** (primary) — Manufacture and dispense compounded products under the company’s Section 503B strategy. - **Women patients and consumers** (primary) — Buy or use the products for contraception, sexual health, vaginal health, menopause and related conditions. - **Strategic collaborators and grant funders** (secondary) — Provide non-dilutive funding, development support, or commercialization access for specific programs. - OB-GYNs and women’s health clinicians prescribing or recommending products - Telehealth platforms and partners distributing consumer health products - 503B outsourcing facilities supporting compounded prescription products - Women seeking non-hormonal contraception or sexual health options - Women seeking vaginal microbiome, menopause, or pelvic health solutions ## Geography The company is headquartered in the United States and its near-term commercial plans are centered on the U.S. market. It sources some vaginal probiotics from Europe for its consumer health strategy, but the core development, regulatory and commercialization work is U.S.-focused. - United States is the main market for prescription and consumer launches - U.S. FDA regulatory pathway drives development and commercialization timing - European sourcing supports vaginal probiotic consumer health products - No disclosed country revenue breakdown in the provided excerpts - Geographic exposure is concentrated in U.S. clinical and commercial execution ## Strategy Dare is pursuing a capital-efficient transition from a development-stage biotech into a company with near-term commercial products and a broader women’s health portfolio. Its strategy is to use third-party manufacturing, strategic partnerships and targeted digital/provider marketing to avoid building a large internal sales force while still creating a commercial platform for future pipeline assets. - **Launch near-term commercial products** (short-term) — Creates initial revenue and market presence without building a full sales infrastructure. - **Pursue capital-efficient commercialization** (short-term) — The company lacks internal sales and distribution capabilities, so partnerships reduce fixed costs and execution risk. - **Advance late-stage women’s health pipeline** (medium-term) — Clinical progress supports future FDA-approved products and longer-term value creation. - **Reduce dependence on dilutive capital** (medium-term) — Management wants commercial and grant funding to help fund operations and reduce financing pressure. - Commercialize DARE to PLAY Sildenafil Cream under Section 503B - Advance DARE-HRT1 toward late-2026 availability - Build consumer health products through partners, not owned distribution - Use digital and provider education to create brand awareness - Keep R&D focused on late-stage and grant-supported programs ## Risks The company remains highly dependent on external capital, clinical success and execution of a still-developing commercialization model. Its business also carries typical biotech risks around regulatory approval, product launch timing, manufacturing transfer, and the possibility that near-term revenue remains immaterial or delayed. - **Insufficient capital to fund operations and development** [critical] — The company states it may need to delay, scale back, or cease programs if it cannot raise funds on acceptable terms. - **Nasdaq listing compliance** [high] — Failure to meet continued listing standards could impair liquidity and access to capital. - **Clinical development and regulatory approval risk** [high] — Pipeline value depends on successful IND filings, clinical studies and FDA outcomes. - **Commercial launch and adoption risk** [high] — Near-term products may not generate meaningful revenue if provider adoption or consumer demand is weak. - **Dependence on third parties** [medium] — The company relies on outsourcing facilities, collaborators and marketing partners rather than owned infrastructure. - Capital shortfall could delay or stop development programs - Nasdaq listing compliance remains a risk for financing access - Commercial launches may generate immaterial revenue initially - Clinical and regulatory setbacks could impair pipeline value - Third-party manufacturing and partners add execution risk ## Accounting The most important accounting issue is the company’s heavy reliance on grant funding, collaboration arrangements and milestone-based obligations, which can create timing differences between cash received and expense recognition. Investors should also watch going-concern disclosures, stock-based compensation, and any impairment or valuation judgments tied to in-licensed rights and development assets. - **Grant accounting and deferred grant funding** — Affects cash, liabilities and the timing of R&D expense recognition - **Going-concern assessment** — Can affect disclosure, valuation assumptions and investor risk perception - **Milestone and in-license obligations** — Can create lumpy operating expenses or accrued liabilities - **Stock-based compensation** — Impacts reported operating loss and non-cash expense trends - Grant funding affects deferred grant liabilities and project expense timing - Milestone obligations under in-license deals can create future expense spikes - Stock-based compensation is a meaningful G&A and R&D cost component - Going-concern assessment depends on future financing and launch success - Intangible asset and royalty transaction valuations may require judgment --- *Last updated: 2026-04-28T20:01:25.729581+00:00*